Cavan Appoints Dr. Manju Sharma MD and Doctor of Naturopathy to Advisory Board
17 Juni 2014 - 2:00PM
Marketwired
Cavan Appoints Dr. Manju Sharma MD and Doctor of Naturopathy to
Advisory Board
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 17, 2014) -
CAVAN VENTURES INC. (TSX-VENTURE:CVN) ("Cavan" or the "Company") is
pleased to provide a corporate update in regards to the continuing
exploration of the potential of the Medical Marijuana and
Hemp/Cannabinoid industry.
Cavan Ventures Inc. previously announced (see news release dated
2014-03-25) the diversification of its growth plan into the Medical
Marijuana and Hemp industry. To accelerate this process, Dr. Manju
Sharma has joined the Company as its newest member to the advisory
board.
Dr. Manju Sharma is a medical doctor, working currently as a
scientist at Vancouver Prostate Centre, Vancouver General Hospital
for the last 5 years. Prior to this she worked in the department of
Pathology and Lab Medicine, VGH for 10 years on various projects
including molecular diagnosis of tuberculosis, multi-drug resistant
tuberculosis, human solid tumors, kidney disorders, medicinal
herbal plants like Echinacea which is widely used all over Europe
and North America for the treatment of cough and cold: active
principles and their mode of action on various human viral and
bacterial diseases. She has published over 70 papers in medical
journals and has made several presentations in the field of
Medicine.
Though trained in Allopathic or Western medicine, she has been
always intrigued by the power of alternative /herbal medicine for
e.g., Cannabis plant. The therapeutic properties of the hemp plant,
Cannabis sativa, have been known for many years, but the
recreational use of its psychoactive effects has restricted its
possible pharmaceutical application. To date, cannabinoids have
been successfully used in the treatment of nausea and vomiting, two
common side effects that accompany chemotherapy in cancer patients.
Most non-THC plant cannabinoids e.g. cannabidiol and cannabigerol,
seem to be devoid of psychotropic properties. Her paper on, "In
vitro anticancer activity of plant-derived cannabidiol on
prostate cancer cell lines", has been accepted in the Journal of
Pharmacology and Pharmacy and will go on-line in July, 2014. Her
overall findings support the concept that cannabidiol, which lacks
psychotropic activity, may possess anti-inflammatory and anticancer
property. Cannabidiol and other non-habit forming cannabinoids
could be used as novel therapeutic agents for the treatment of
prostate cancer. Her case studies confirmed cannabinoid efficacy in
reducing muscle spasticity in multiple sclerosis (Hornby and Sharma
2010), pain levels over a 12 month period (Hornby and Sharma 2009)
and Cannabis responsive head injury induced multiple disabilities
(Sharma. 2012).
She is also working as a Natural Health consultant and analyzing
cannabinoids (THC, CBD and CBN) by Gas Chromatography for the
members of Green Cross Society of BC. This helps the members to
choose the right cannabis strain for smoking and thereby help them
to regulate their cannabis dose. Cannabis capsules are also
available for the patients who want to take this medicine orally.
Cannabis with high CBD and low THC are heat treated, chemically
characterized using chromatography and Cannacaps (capsules) are
available for oral use. At Green Cross society of BC, Cannacaps
with high CBD and low THC are made available to the patients of
breast cancer, prostate cancer and other medical problems like
pain, inflammation, epilepsy, spasticity and eating disorders.
To view references published in the last 8 years, visit the
following link:
http://media3.marketwire.com/docs/CVN%20References.pdf.
Peter P. Swistak, President/CEO of Cavan Ventures Inc., states,
"The depth and scope of Dr. Sharma's knowledge is unparalleled and
Cavan is very fortunate to have access to this knowledge as we
believe Dr. Sharma is the best in her field with an extensive bio
and published research. Dr. Sharma will add tremendous value,
credibility and unique knowledge to Cavan in its analysis of the
Medical Marijuana and Hemp/Cannabinoid industry, and potential
opportunities in that industry. We are excited to have Dr. Sharma
available to us while we conduct due-diligence in the
Cannabinoid/Medicinal Marijuana space."
At this time, no transactions are in place, nor is there any
assurance that a new project will be concluded in the future.
For more information visit the website at
www.cavanventuresinc.com.
ON BEHALF OF THE BOARD
Peter P. Swistak, President
Forward-Looking Statement: Certain statements in this
release are forward-looking statements, which reflect the
expectations of management regarding the Company's plans with
respect to its existing graphite interests, future financings, and
the analysis and investigation of the medical marijuana sphere.
Forward-looking statements consist of statements that are not
purely historical, including any statements regarding beliefs,
plans, expectations or intentions regarding the future and
statements concerning the anticipated drilling programs, future
financings, and the Company proceeding with any transactions in the
medical marijuana sphere. Such statements are subject to risks and
uncertainties that may cause actual results, performance or
developments to differ materially from those contained in the
statements. No assurance can be given that any of the events
anticipated by the forward-looking statements will occur or, if
they do occur, what benefits the Company will obtain from them. In
particular, the Company cautions that any financings or potential
transactions cannot be predicted with certainty, and there can be
no assurance at this time that all required or desirable approvals
and consents to affect future financings or proposed transactions
will be achieved at all. These forward-looking statements reflect
management's current views and are based on certain expectations
and assumptions which may prove to be incorrect. A number of risks
and uncertainties could cause our actual results to differ
materially from those expressed or implied by the forward-looking
statements, including factors beyond the Company's control. These
forward-looking statements are made as of the date of this news
release.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Cavan Ventures Inc.1-604-683-3995 or Toll Free:
1-888-945-4770www.cavanventuresinc.com
Cavan Ventures Inc. (TSXV:CVN)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Cavan Ventures Inc. (TSXV:CVN)
Historical Stock Chart
Von Jun 2023 bis Jun 2024